RONY CARLOS PRETI
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/33 - Laboratório de Oftalmologia, Hospital das Clínicas, Faculdade de Medicina
LIM/33 - Laboratório de Oftalmologia, Hospital das Clínicas, Faculdade de Medicina
5 resultados
Resultados de Busca
Agora exibindo 1 - 5 de 5
- Structural and Functional Assessment of Macula in Patients with High-Risk Proliferative Diabetic Retinopathy Submitted to Panretinal Photocoagulation and Associated Intravitreal Bevacizumab Injections: A Comparative, Randomised, Controlled Trial(2013) PRETI, Rony Carlos; RAMIREZ, Lisa Marie Vasquez; MONTEIRO, Mario Luiz Ribeiro; PELAYES, David E.; TAKAHASHI, Walter YukihikoPurpose: To compare the efficacy of therapy with panretinal photocoagulation (PRP) and intravitreal bevacizumab (IVB) injections versus PRP alone in patients with high-risk proliferative diabetic retinopathy (HR-PDR) with a 6-month follow-up. Methods: Forty-two patients with HR-PDR were prospectively studied in a randomised, masked, controlled trial. Both eyes of each patient were randomised either to the study group (SG) receiving PRP plus IVB injections or the control group (CG) receiving PRP alone. Mean change in visual acuity (VA), optical coherence tomography-measured fovea! thickness (FT) and macular volume (MV) were compared. Results: Intergroup comparisons showed no significant difference in VA while FT exhibited a significant (p < 0.05) difference at 1 month of follow-up and MV was significantly reduced at the 1- and 3-month follow-up. Compared to baseline, VA was significantly worse at all follow-ups in the CG and was stable in the SG. FT increased significantly in the CG from baseline to the 1- and 6-month follow-ups and in the SG, no significant difference was observed. MV was significantly increased in the CG during all follow-up periods. Conclusion: In HR-PDR, using IVB injections as adjuvant treatment to PRP reduces the VA deterioration and results in decreased FT and MV measurements compared to PRP alone.
conferenceObject Intravitreal Ranibizumab Combined with Panretinal Photocoagulation in Patients with Treatment-Naive Proliferative Diabetic Retinopathy(2013) FERRAZ, Daniel; SOPHIE, Raafay; BITTENCOURT, Millena; PRETI, Rony; VAZQUEZ, Lisa; MOTTA, Augusto; HANOUT, Mostafa; SEPAH, Yasir; Quan Dong Nguyen; TAKAHASHI, Walter- Use of intravitreal bevacizumab or triamcinolone acetonide as a preoperative adjunct to vitrectomy for vitreous haemorrhage in diabetics(2013) FERRAZ, Daniel Araujo; MORITA, Celso; PRETI, Rony Carlos; NASCIMENTO, Vinicius Paganini; MAIA JUNIOR, Otacilio Oliveira; BARROS, Andre Carvalho de; TAKAHASHI, Beatriz Sayuri; TAKAHASHI, Walter YukihikoPurpose: To evaluate the effect of preoperative intravitreal bevacizumab (IVB) or triamcinolone (IVT) on the rate of early postvitrectomy hemorrhage in proliferative diabetic retinopathy (PDR). Methods: Eligible eyes were assigned randomly to 1 of 3 groups: the IVB group received 1.25 mg bevacizumab, the IVT group received 4,0mg triamcinolone and the control group underwent a sham procedure. The primary outcome measure was the incidence of early postvitrectomy hemorrhage. Secondary outcome measures included changes in visual acuity (BCVA) and adverse events. Results: Twenty and seven eyes, 9 in each group were randomized. The incidence of vitreous hemorrhage was lower in the IVB group (p=0.18). Postoperative vitreous hemorrhage at 1 month also was less in the IVB group compared with the control group (p >= 0.05). The rate of bleeding immediately after surgery was higher in IVT group with 4 (44.4%) cases. The overall mean visual acuity was 1.72 +/- 0.37 logMAR preoperatively and 1.32 +/- 0.73 logMAR in 6 months after surgery. Accessing visual acuity by group evidenced that the IVB group had initial mean logMAR VA of 1.87 and 1.57 logMAR VA at the six months (p = 0.84). In IVT group, initial mean VA was 1.75 logMAR and 0.96 logMAR VA at six months (p <= 0.001). And in control group, the initial mean VA was 1.85 logMAR and 1.57 logMAR VA at six months (p= 0.34). Conclusion: Intravitreal injection of bevacizumab 1 week before vitrectomy seems to reduce the incidence of early postvitrectomy hemorrhage in diabetic patients. There was a better visual acuity outcome in the triamcinolone group.
conferenceObject EVALUATION OF CHOROIDAL THICKNESS IN HIGH-RISK PROLIFERATIVE DIABETIC RETINOPATHY TREATED WITH PANRETINAL PHOTOCOAGULATION ASSOCIATED OR NOT WITH INTRAVITREAL BEVACIZUMAB INJECTIONS: A 3 MONTHS, RANDOMIZED, CONTROLLED AND MASKED CLINICAL TRIAL(2013) PRETI, Rony; MUTTI, Anibal; VAZQUEZ, Lisa; FERRAZ, Daniel; ZACHARIAS, Leandro; CARRA, Mario; PELAYES, David; MONTEIRO, Mario; TAKAHASHI, Walter- Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial(2013) PRETI, Rony Carlos; RAMIREZ, Lisa Mariel Vasquez; MONTEIRO, Mario Luiz Ribeiro; CARRA, Mario Kehdi; PELAYES, David E.; TAKAHASHI, Walter YukihikoPurpose To compare the effect on contrast sensitivity (CS) measurements of panretinal photocoagulation (PRP) associated with intravitreal bevacizumab (IVB) injections versus PRP alone in high risk proliferative diabetic retinopathy (HR-PDR). Design Prospective, randomised, masked, controlled trial. Participants 42 patients with HR-PDR with visual acuity >= 20/200. Methods Eyes were randomised to one of two groups: one underwent PRP and IVB injections (study group) and the other PRP alone (control group). PRP was performed three times during the study and IVB injection was administered twice. Main outcome measures Mean change in CS threshold scores between and within groups, from baseline to 6 months. Results Seven patients presented with vitreous haemorrhage and were removed from the study. Mean results for CS threshold (at 1.5, 3, 6, 12 and 18 cycles per degree (cpd) frequencies) for patients with and without diabetic macular oedema showed no significant differences (p>0.05 for all comparisons) between the two groups. In 35 eyes in the control group, compared with baseline values, there was significant worsening (p<0.05) of CS at 1.5, 12 and 18 cpd after 1 month, at 12 cpd after 3 months, and at 6 and 12 cpd after 6 months. In the study group, there was significant improvement in CS at 3 cpd, 3 months after treatment. Conclusions In eyes with HR-PDR, PRP treatment is associated with deterioration of CS while adjuvant use of bevacizumab prevents such deterioration. CS evaluation seems to support the adjuvant use of bevacizumab when using PRP for the treatment of HR-PDR.